SPY363.22+5.76 1.61%
DIA300.43+4.54 1.53%
IXIC12,036.79+156.15 1.31%

Varian And Cincinnati Children's/UC Health Proton Therapy Center Announce Initial Patient Treated In FAST-01 First Human Clinical Trial Of FLASH Therapy For Cancer

- First patient in the world to participate in a clinical trial of FLASH therapy - Physicians and researchers at Cincinnati's Children's/UC Health Proton Therapy Center are using a Varian ProBeam® proton

· 11/19/2020 08:28


- First patient in the world to participate in a clinical trial of FLASH therapy
- Physicians and researchers at Cincinnati's Children's/UC Health Proton Therapy Center are using a Varian ProBeam® proton therapy system modified to deliver radiation treatment at ultra-high dose rates
- FLASH therapy delivers radiation at ultra-high dose rates up to 100 times faster compared to conventional radiation therapy
- Study was designed in collaboration with the FlashForwardTM Consortium

PALO ALTO, Calif., and CINCINNATI, Ohio, Nov. 19, 2020 /PRNewswire/ -- Varian (NYSE:VAR) and the Cincinnati Children's/UC Health Proton Therapy Center today announce the start of the first clinical trial of FLASH therapy as part of the recently opened FAST-01 study (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases). The clinical trial involves the investigational use of Varian's ProBeam® particle accelerator modified to enable radiation therapy delivery at ultra-high dose rates (dose delivered in less than 1 second) and is being conducted at the Cincinnati Children's/UC Health Proton Therapy Center with John C. Breneman M.D., Medical Director of the center, serving as principal investigator.